Clinical Trials · NCT01766245
A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 28
- Start date
- Dec 2012
- Locations
- 1 site, Germany
- Primary endpoint
- Area under the plasma semaglutide concentration curve